Prostate cancer is the leading cancer among Kenyan men, with an estimated 3,582 men being diagnosed with the disease at some ...

Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial approval, data from pancreatic cancer trials presented at ASCO GI Symposium, and ...

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a plenary prostate cancer session and a ...

The 2026 European Association of Urology (EAU) annual meeting featured an advancements in metastatic castration resistant prostate cancer (mCRPC) therapy session and a presentation by Dr. Giulio ...

First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to ...

The market for radioligand therapies is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being ...

Pharmacokinetic analysis revealed sustained activity at 15 days, a finding corroborated by imaging that demonstrated prolonged tumor retention of the therapeutic agent. Importantly, researchers found ...

The new treatment uses the unique biology of the cancer itself to guide radiotherapy delivery, even in tumors that are in motion.

In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit desired safety and ...

Prostate cancer is one of the most common cancers affecting men around the world. In many countries, including Germany, it is the most frequently diagnosed cancer in men. Each year, about 65,000 men ...

Profound Medical Corp. (NASDAQ:PROF) Q4 2025 Earnings Call Transcript March 6, 2026 Operator: Good day, and thank you for ...